NanoViricides Announces Closing of ~$2 Million Registered Direct Offering

May 18, 2026 11:55 PM

NanoViricides, Inc. (NYSE American:NNVC) ("NanoViricides" or the "Company"), a clinical stage, leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine technology that viruses and their variants cannot escape, today announced the closing of its previously announced registered direct offering (the "Offering") of 1,333,334 million shares of common stock (or pre-funded warrants in lieu thereof),...

Read more

Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026

May 18, 2026 4:05 PM

DENVER, CO / ACCESS Newswire / May 18, 2026 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on advancing innovative medicines for complex central nervous system diseases to improve the quality of life for patients, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2026 Investor Conference, taking place virtually on Thursday, May...

Read more

The Assistance Fund Opens New Program for Focal Segmental Glomerulosclerosis (FSGS)

May 18, 2026 12:50 PM

The Assistance Fund, an independent charitable patient assistance organization that helps patients and families facing high medical out-of-pocket costs, today announced the launch of a new financial assistance program for people living with focal segmental glomerulosclerosis (FSGS). The program is designed to help eligible individuals pay for their out-of-pocket medical costs for treatment, such as copays, coinsurance, deductibles, health...

Read more

Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering

May 18, 2026 12:15 PM

Sunshine Biopharma Inc. (NASDAQ:SBFM) (the "Company"), a pharmaceutical company offering and developing life‑saving medicines across oncology, antivirals, and other key therapeutic areas, today announced the pricing of a public offering made on a reasonable best efforts basis with gross proceeds to the Company expected to be approximately $6.0 million, before deducting placement agent fees and other offering expenses payable by the Company.The...

Read more

Europe's Healthcare IT Market Enters the 2027 Readiness Cycle as Black Book Names 26 Top Client-Rated Vendors During HIMSS26 Week in Copenhagen

May 18, 2026 12:00 PM

Black Book Research today announced its 2026 European Healthcare IT Client Satisfaction Honors, recognizing 26 healthcare technology vendors and platforms whose strongest client-facing performance aligns with the next phase of European digital health: trusted data, cross-border interoperability, AI accountability, cybersecurity resilience, cloud modernization, enterprise imaging liquidity, analytics readiness and clinical workflow...

Read more

GLUTRONICS(TM) Appoints Brad Boruk as Co-Chief Executive Officer

May 18, 2026 9:55 AM

GLUTRONICS™, a medical technology startup focused on non-invasive glucose monitoring, today announced the appointment of Brad Boruk as Co-Chief Executive Officer. Boruk will serve alongside Co-CEO Dr. Hoon Kim, who continues to lead the company's technology development and research initiatives. The appointment reflects the company's intent to expand its commercial and strategic capabilities as it advances its technology toward potential future...

Read more

CVS Health: A Second Chance at Life Through Heart Transplant and Ongoing Care

May 18, 2026 9:00 AM

Originally published on CVS Health Company NewsroomKey pointsAfter smoking for decades and surviving two heart attacks, Bill Allison learned that he needed a heart transplant - and that making immediate, lasting life changes was essential.Beyond dispensing medications, Bill's CVS Specialty pharmacist, Amy Guard, has supported him throughout his post transplant journey with ongoing medication counseling and encouragement."Listen to your doctors,...

Read more

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides

May 18, 2026 8:30 AM

NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, emphasizes the critical need for a revolutionary, broad-spectrum, antiviral drug like NV-387 as another severe Ebolavirus outbreak has occurred in the Eastern part of DR Congo (DRC), with spillage across the border into Uganda."We believe NV-387 could be effective against the Bundibugyo strain of Ebola that is...

Read more

Regulatory Derogation and Reimbursement in France Enable Life-Saving Use of XVIVO's Heart Technology

May 18, 2026 8:10 AM

XVIVO Perfusion AB (STO:XVIVO)(LSE:0RKL)(FRA:3XV) - Hôpital La Pitié-Salpêtrière (Sorbonne University) in Paris, France, has, since the approval of a regulatory derogation for XVIVO's heart technology back in December 2025, performed 11 heart transplants that would otherwise not have taken place, saving precious lives. In addition, XVIVO's heart technology has now also received reimbursement in France.A regulatory derogation allows a medical...

Read more

June 29 Marijuana Rescheduling Hearing Faces Constitutional Issues Before It Even Begins

May 18, 2026 6:00 AM

The federal government's highly publicized plan to move marijuana from Schedule I to Schedule III faces a structural legal problem that political momentum cannot erase: the Department of Justice has formally admitted in federal court that the DEA Administrative Law Judge ("ALJ") structure violates the United States Constitution, while the same administrative system is still expected to conduct marijuana rescheduling hearings. This...

Read more

Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference

May 18, 2026 2:40 AM

Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ¹⁷⁷Lu-SN201 in patients with advanced solid tumors, including case studies showing visible tumor...

Read more

CK Life Sciences' Sequencio Therapeutics Appoints Emily Tan as Chief Operating Officer

May 18, 2026 1:42 AM

Sequencio Therapeutics, a subsidiary of CK Life Sciences Int'l., (Holdings) Inc. ("CK Life Sciences", Stock Code:0775) today announced the appointment of Emily Tan as Chief Operating Officer. A 30-year biopharmaceutical veteran, Ms Tan will oversee the company's global operations and drive execution across its development pipeline.Ms Tan joins Sequencio Therapeutics with an extensive track record across global pharmaceutical companies, leading...

Read more

MedSyntra Advances Sovereign Healthcare AI Vision and Appoints Dr George Syrmalis to Board of Directors

May 17, 2026 2:00 AM

MedSyntra, a company operating at the intersection of healthcare, artificial intelligence, and sovereign medical data infrastructure, today announced the continued expansion of its strategic and governance capabilities - including the appointment of Dr George Syrmalis to its Board of Directors - as it advances the development of institutionally governed healthcare AI ecosystems. The company is focused on building scalable healthcare...

Read more

State Cannabis Companies Rushed To Apply for DEA Registration but DEA Cannot Rewrite Marijuana Federal Register Rules With a Press Statement

May 16, 2026 11:30 AM

The moment the federal government opened the door to new Schedule III marijuana registration pathways, state cannabis companies rushed toward it. Major operators began filing DEA registration applications almost immediately, hoping for:federal legitimacy,easier banking,and relief from crushing IRS 280E taxes.But there is one major problem:The DEA's own binding Final Rule published in 2020 says many of those companies spent years operating...

Read more

Europe's Hospital Cyber Risk Has Moved From Data Theft to Care Disruption, Black Book Study Warns Ahead of HIMSS26 Europe

May 16, 2026 10:00 AM

Black Book Research today released findings from its Pre-HIMSS26 Europe Copenhagen Cybersecurity Demand Pulse Survey, warning that hospital cyber risk across Europe has entered a more dangerous phase: attacks are no longer viewed primarily as privacy events, compliance events, or IT disruptions. They are now being evaluated as direct threats to care delivery.The survey of 284 self-identified HIMSS26 attendees from European hospital, health...

Read more

ClinicsSpots Named Medical Prep One of the Top Online Medical Assistant Training Programs of 2026

May 16, 2026 7:30 AM

In its 2026 review of medical assistant programs, ClinicsSpots ranked Medical Prep among the leading options for students pursuing medical assistant training. The recognition reflects Medical Prep's emphasis on accessible career guidance, certification preparation, flexible learning considerations, and practical program-selection support. For prospective students comparing medical assistant pathways, the updated MedicalPrep training resource...

Read more

Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate

May 15, 2026 6:00 PM

Onco-Innovations Limited (CBOE CA:ONCO)(OTCQB:ONNVF)(Frankfurt:W1H)(WKN: A3EKSZ) ("Onco" or the "Company") is pleased to announce that it has advanced its Chemistry, Manufacturing and Controls ("CMC") development program through the initiation of analytical method validation activities for assay, related substances, and residual solvents for A83B4C63, the active pharmaceutical ingredient ("API") for Onco's exclusively-licensed PNKP Inhibitor...

Read more

Ensysce Biosciences Reports First Quarter 2026 Financial Results

May 15, 2026 4:15 PM

Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company pioneering next-generation pain and central nervous system therapeutics engineered to minimize abuse and overdose risk, today reported financial and operational results for the first quarter ended March 31, 2026."The first quarter of 2026 delivered meaningful operational and clinical momentum across our pipeline, underscoring the...

Read more

Wellgistics Health to Announce First Quarter 2026 Financials on Tuesday May 19, 2026

May 15, 2026 4:01 PM

Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced that it will report financial results for the first quarter of 2026 on Tuesday, May 19, 2026.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader integrating its proprietary pharmacy dispensing optimization artificial intelligence...

Read more

Glidewell TV Celebrates One Year of On-Demand Dental Education

May 15, 2026 11:00 AM

Glidewell, America's foremost dental laboratory and longtime provider of world-class continuing education solutions, is celebrating the one-year anniversary of Glidewell TV, reflecting on the significant growth and looking ahead to an expanded slate of original programming as the free streaming service enters its second year.Positioned as the "Netflix of dentistry," Glidewell TV was launched to give dental professionals access to practical,...

Read more